Most of the AI tools examined were Class II devices, which are considered to have a moderate risk to patients and are typically approved based on their similarity to existing technologies.
Most of the AI tools examined were Class II devices, which are considered to have a moderate risk to patients and are typically approved based on their similarity to existing technologies.